Needs and obstacles of uniform immunisation schedules in the European Union by Wiese-Posselt, Miriam et al.
Bundesgesundheitsbl 2009 · 52:1099–1104
DOI 10.1007/s00103-009-0954-x
Online �ubli�ie�t: 21. O�t�be� 2009       
© S��inge�-Ve�lag 2009
M. Wiese-Posselt · S. Reiter · A. Gilsdorf · G. Krause
De�a�tment f�� Infecti�us Disease E�idemi�l�gy, R�be�t K�ch-Institut, Be�lin
Needs and obstacles of uniform 
immunisation schedules 
in the European Union
In der Diskussion
Childhood immunisation schedules in the 
different member states (MS) of the Eu-
ropean Union (EU) show varying diver-
sity in respect to age of administration as 
well as types and numbers of vaccinations 
[1]. These schedules are generally devel-
oped at the national level by the respec-
tive national committees on immunisa-
tion (NCI) and are influenced by local 
requirements. With increasing globali-
sation of vaccine development, licensing 
and marketing it might appear a logical 
consequence that immunisation sched-
ules should therefore become more uni-
form within the EU.
The European Commission (EC) has 
started an initiative for a council recom-
mendation on cross-border aspects of 
childhood immunisation. The objective 
of this initiative is to establish a scientif-
ically substantiated and flexible immun-
isation schedule with the widest possible 
time margins in which a child should be 
immunised against a set of priority diseas-
es (reference immunisation schedule) [2, 
3]. The European Centre for Disease Pre-
vention and Control (ECDC) has recently 
addressed this issue by generating scien-
tific advice with the objective to realise a 
reference childhood immunisation sched-
ule regarding diphtheria-tetanus-pertus-
sis (DTP) vaccination [2]. Although the 
EC has stated that the initiative does not 
seek to harmonise the different national 
immunisation schedules, the aim to pro-
duce one scientifically substantiated Euro-
pean immunisation schedule in respect to 
timing and number of doses of, e.g., DTP 
vaccination in childhood implies that this 
reference schedule might be the only one 
scientifically maintainable. However, dif-
ferent national immunisation schedules 
could be well justified and a unification 
of immunisation schedules across EU MS 
may lead to only limited benefits or even 
to detrimental effects. In the following we 
aim to address those issues focussing on 
the public health perspective.
Availability of evidence
Looking at the large variation between 
immunisation schedules across the EU, 
one wonders whether these are in fact 
all well founded by evidence. For exam-
ple, currently children and adolescents re-
ceive between 4 and 7 doses of diphthe-
ria and tetanus (DT)-containing vaccines 
until their 18th birthday depending on the 
different national immunisation recom-
mendations [1]. If national committees 
on immunisation (NCI) have come up 
with such extreme differences it may be 
an indication that those committees have 
generated their recommendations on the 
basis of divergent or lacking evidence. 
The committee’s judgement on the pub-
lic health relevance of a respective vacci-
nation could then have resulted in differ-
ent recommendations. This may indeed 
be detrimental in convincing clinicians, 
vaccinees and their care takers for a rec-
ommended immunisation schedule and 
it may fuel scepticism against immunisa-
tion in general. If the diversity in nation-
al immunisation recommendations is in 
fact caused by lack of evidence, then the 
logical consequence would be to increase 
every effort to generate the necessary ev-
idence.
There are already various approach-
es to intensify the evidence-based public 
health (EB-PH) methodology in the de-
cision making process for immunisation 
schedules [4]. NCI and national public 
health institutions are already increasing 
their efforts towards transparent decision 
making procedures and comprehensible, 
evidence-based recommendations. Those 
efforts at the national level could well be 
supported and facilitated by multination-
al (e.g. EU) activities, for example by con-
ducting and analysing systematic litera-
ture searches and by facilitating, coordi-
nating or conducting those epidemiolog-
ical studies needed to answer the relevant 
open questions. The results could then be 
taken into consideration by the different 
NCI together with other local determi-
nants. Such support, for example by the 
ECDC, would be of immense European 
added value.
However, in order to make such prod-
ucts useful for the NCI, there must be con-
sensus on how to collect, structure and 
present the scientific evidence. This in-
cludes a standardised approach of system-
atic literature searches, a common meth-
odology to identify and to grade the qual-
ity of evidence and the strength of recom-
mendation. The Grading of Recommen-
dations Assessment, Development and 
Evaluation (GRADE) Working Group 
and the Scottish Intercollegiate Guide-
lines Network (SIGN) have already devel-
oped very useful concepts in this field [5, 
6]. The ECDC and the Robert Koch Insti-
tute have just initiated a process in which 
the application of GRADE and SIGN for 
public health recommendations is be-
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ing examined together with experts from 
national public health institutions. This 
could eventually lead to a common con-
cept of how evidence for public health 
recommendations is to be processed and 
presented. If such an agreement could be 
reached within the EU, this could set the 
foundation for the gradual development 
of uniform immunisation schedules.
Reasons for differences in 
national immunisation schedules
Such foundation of evidence will lead to 
more consistent immunisation schedules, 
but NIC may well come up with different 
recommendations even if the same evi-
dence is used. The reason for this is that 
the country specific situation may differ 
in many ways that may have an impact on 
the immunisation strategy. The most im-
portant topics to consider here are coun-
try specific differences in (a) values and 
goals, (b) epidemiological situation, (c) 
healthcare delivery system, (d) logistics 
of vaccine delivery, and (e) economic sit-
uation:
Values and goals
Immunisation schedules are a specific 
form of public health interventions and 
are influenced by respective values and 
health goals of a society. The acceptability 
of a recommended vaccine among those 
who prescribe and administer it, as well 
as among the recipients and their care tak-
ers is of immense importance for the suc-
cess of an immunisation strategy. There-
fore, feasibility of an immunisation pro-
gramme is closely linked to acceptability 
which in turn is largely influenced by cul-
tural values of a society. The goal of an im-
munisation programme may be to reduce 
the disease burden in risk groups or in 
the whole population. It may include oth-
er positive epidemiological effects such 
as herd immunity or the eradication of a 
pathogen or it can be limited to individ-
ual protection. Some EU MS already de-
fine their aim quantitatively, e.g. a 90% re-
duction of a vaccine preventable disease 
(VPD) within a certain time frame. This 
is of course likely to affect the immunisa-
tion strategy and thus the respective im-
munisation schedule.
The WHO goal of measles eradication 
by 2010 in the European region is such 
an example [7]. The target is to eradicate 
measles or reduce morbidity and mortali-
ty due to measles. Children should, there-
fore, receive two doses of measles-con-
taining vaccine but it is not predetermined 
which schedule should be used (two dos-
es within the second year of life or first 
dose in the second year of life and the sec-
ond dose before school entry or even lat-
er) [1].
This means that before one uniform 
immunisation schedule can be estab-
lished, agreement is needed about the 
public health goals to be achieved.
Different epidemiological 
situations
Although, one might expect very simi-
lar living conditions across the EU, differ-
ences in the local epidemiology may well 
justify different immunisation schedules. 
The annual epidemiological report on 
communicable diseases in Europe pro-
duced by the ECDC shows important dif-
ferences in the epidemiology of VPDs [8]. 
For diphtheria for example, high numbers 
of cases were reported from Latvia (32 cas-
es in 2006), while in other MS no case of 
diphtheria has occurred in recent years 
[8]. Although all European countries have 
integrated pertussis vaccination into their 
routine immunisation schedule, pertussis 
incidences vary between <0.1 (e.g. Roma-
nia) and 142.0/100,000 population (Nor-
way) in 2006 [8].
Hepatitis B is another example: the re-
ported surveillance data show a hepati-
tis B incidence between 0.29 (France) and 
10.0/100,000 population (Bulgaria) in 
2006 [8]. The disease burden of hepatitis 
B is not only defined by the incidence but 
other possible influencing factors have to 
be taken into account, such as age-specific 
incidences, prevalence of HBsAg carriage, 
the detection of persons at high risk for in-
fection and the frequency of hepatitis B in 
these persons (i.v. drug users), success of 
infection control measures already imple-
mented etc. [9]. As a result of such consid-
erations universal childhood vaccination 
against hepatitis B can be very effective in 
some MS; however in other MS with a low 
incidence a selective programme may be 
more appropriate.
Different health care systems
The burden of disease is not only defined 
by the incidence but also by factors which 
largely depend on an individual country’s 
health care system. The way curative care 
is organised may have large implications 
on the societal cost of one illness and even 
on the case fatality rate and therefore, on 
local immunisation recommendations.
Immunisation also has to be viewed 
in relation to the availability of other pre-
ventive options such as hygienic measures 
or chemoprophylaxis. Depending on the 
availability and (cost) effectiveness of such 
complementary measures in the different 
MS the national immunisation strategies 
might also differ.
Different logistics of 
vaccine delivery
In order to accomplish high vaccination 
coverage, the timing of a certain vaccina-
tion should be considered in a timeframe 
when children are easy to reach. Immun-
isation can be promoted in an optimal 
way if vaccinations are given at the same 
time that routine child health screenings 
are scheduled. Depending on the system 
of childcare and age of school entry, chil-
dren are exposed and reachable for im-
munisation at different ages in the differ-
ent MS. That also affects the immunisa-
tion schedules and leads to the diversity 
between MS.
Different economic situations
All above mentioned factors will result 
in different costs and thus have implica-
tions on the cost effectiveness or cost ben-
efit analysis in the different MS. Budgets 
for health services vary greatly between 
MS and the budgets for immunisation in 
a respective country may simply not al-
low a change in the immunisation sched-
ule, which will result in increased expen-
ditures, even if it is cost effective on the 
overall societal level. Therefore, a vac-
cine might not be recommended for rou-
tine immunisation although there is high 
1100
In der Diskussion
|  Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 11 · 2009
quality evidence on the effectiveness and 
safety of this vaccine.
Justifications for uniform 
immunisation schedules
As described above, we could detect nu-
merous reasons for the diversity of na-
tional immunisation schedules in Eu-
rope. However, the European Commis-
sion (EC) is preparing a council recom-
mendation on diphtheria-tetanus-pertus-
sis (DTP) vaccination in childhood and 
the ECDC has created the ECDC’s Scien-
tific Panel on Childhood Immunisation 
Schedule (SPACIS) which should give ad-
vice about how to establish a reference im-
munisation schedule regarding DTP vac-
cination in childhood [10]. This panel has 
already developed policy options on how 
to immunise children less than two years 
of age against DTP and regarding minimal 
booster doses which should be given un-
til the 18th birthday. After feedback from 
the MS the draft document of the SPA-
CIS on DTP vaccination is now under re-
vision [10]. In the document it is reported 
that the SPACIS expert panel focused on 
three questions:
F		What is the best age (or age range) to 
start the basic immunisation scheme 
for a combined diphtheria-tetanus-
pertussis (DTP) vaccine?
F		What is the minimum number of 
doses and what are the best immun-
isation intervals to provide sufficient 
protection against DTP in infants 
younger than two years of age?
F		What is the minimum number of 
booster doses that should be adminis-
tered between two and 18 years of age, 
and what are the best intervals be-
tween doses?
More of such activities in respect to other 
VPDs are planned by the EC [2]. The ar-
guments listed to justify uniform immun-
isation schedules are that these schedules 
would (a) be necessary to assure mobili-
ty of EU residents within the EU, (b) al-
low MS to jointly negotiate lower vaccines 
prices with the manufacturers, (c) be lim-
ited to recommending minimal effective 
schedules, (d) reduce the need for clini-
cal trials, (e) facilitate collection of EU-
wide data on evaluation of surveillance 
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Notwendi�keiten und Hürden einheitlicher Impfempfehlun�en  
in der Europäischen Union
�usammenfassun�
Im�fem�fehlungen we�den v�n nati�nalen 
Im�f��mmissi�nen e�a�beitet und �önnen 
sich �wischen den Mitgliedsstaaten (MS) de� 
Eu���äischen Uni�n (EU) e�heblich unte�-
scheiden. Die Eu���äische K�mmissi�n sta�-
tete eine Initiative fü� eine Em�fehlung des 
Rates mit dem Ziel, einen eu���äischen, wis-
senschaftlich fundie�ten Refe�en�-Im�f�a-
lende� fü� Kinde� �u entwic�eln. Unse�e� Mei-
nung nach im�li�ie�t diese Initiative die Etab-
lie�ung eines ein�igen eu���äischen Im�f�a-
lende�s, de� als de� ein�ig wissenschaftlich �u 
�echtfe�tigende bewe�tet we�den �önnte. Die 
E�wa�tungen, dass ein einheitliche� Im�f�a-
lende� die F�ei�ügig�eit v�n EU-Bew�hne�n 
e�leichte�n, die Datene�fassung ve�besse�n 
und die Im�fqu�te e�höhen �önnte, e�scheint 
quantitativ und qualitativ nicht �elevant �de� 
s�ga� ethisch beden�lich. Im�fst�ff��eise 
und de� Beda�f fü� �linische Studien �önnten 
du�ch einheitliche Im�f�alende� gesen�t we�-
den, abe� dies �önnte du�ch alte�native Maß-
nahmen s�ga� effe�tive� gelingen. Auf de� 
ande�en Seite unte�scheiden sich f�lgende 
Fa�t��en �wischen den MS e�heblich und be-
g�ünden unte�schiedliche Im�f�alende�, wie 
a) We�te und Zielset�ungen, b) e�idemi�l�-
gische Lage, c) Gesundheitsve�s��gungssys-
teme, d) Im�fl�gisti� und e) wi�tschaftliche 
Situati�n. Die Ve�einheitlichung v�n Im�f�a-
lende�n s�llte nicht als ��imä�es Ziel gesehen 
we�den, s�nde�n allenfalls als Nebeneffe�t 
inf�lge �unehmende� Einigung übe� Ziele 
und We�te s�wie eine� ve�besse�ten Eviden�-
g�undlage, die v�n nati�nalen Im�f��mmis-
si�nen ve�wendet we�den �önnte.
Schlüsselwörter
Schut�im�fungen · Im�f�alende� · Im�fem�-
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Needs and obstacles of uniform immunisation schedules in the  
European Union
Abstract
Immunisati�n schedules a�e devel��ed by 
nati�nal c�mmittees �n immunisati�n and 
may diffe� c�nside�ably between the Eu���e-
an Uni�n (EU) membe� states (MS). The Eu��-
�ean C�mmissi�n has launched an initiative 
f�� a c�uncil �ec�mmendati�n with the aim 
t� establish a scientifically substantiated �ef-
e�ence childh��d immunisati�n schedule f�� 
the EU. In �u� view this initiative im�lies the 
establishment �f �ne Eu���ean childh��d 
immunisati�n schedule, which c�uld lead t� 
the �e�ce�ti�n that this schedule is the �n-
ly �ne scientifically justified. The ex�ectati�ns 
that �ne unif��m immunisati�n schedule will 
facilitate m�bility �f EU �esidents, im���ve 
data c�llecti�n and inc�ease vaccinati�n c�v-
e�age a�e eithe� quantitatively �� qualitative-
ly n�t �elevant �� even ethically ���blemat-
ic. A�guments that unif��m schedules w�uld 
lead t� l�we� vaccine ��ices and �educe the 
need f�� clinical t�ials a��ea� t� be m��e �el-
evant but c�uld be add�essed m��e effec-
tively by �the� measu�es. On the �the� hand 
the f�ll�wing fact��s may diffe� substantial-
ly between MS and thus su����t diffe�ent im-
munisati�n schedules, such as (a) values and 
g�als, (b) e�idemi�l�gical situati�n, (c) health 
ca�e delive�y system, (d) l�gistics �f vaccine 
delive�y and (e) ec�n�mic situati�n. We a�gue 
that unif��m schedules sh�uld n�t be �e�-
ceived as a g�al in itself but �athe� as a ��ssi-
bly desi�ed by-���duct f�ll�wing inc�easing 
ag�eement �n g�als and values between MS 
and im���ved evidence base t� be used by 
nati�nal c�mmittees �n immunisati�n.
Keywords
Immunisati�n · Immunisati�n schedule · Vac-
cines · Eu���ean Uni�n
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programmes, and (f) increase the vacci-
nation coverage [2, 3, 10]. In the follow-
ing we would like to address those argu-
ments:
Mobility of EU residents
The efforts to establish uniform immun-
isation schedules are often being justified 
by the potential difficulties of EU resi-
dents moving with their children from 
one MS to another one with a different 
childhood immunisation schedule. It is 
being argued that difficulties of complet-
ing an immunisation schedule in another 
country may cause a decrease of the im-
munisation compliance, an increase of the 
workload of healthcare workers and ulti-
mately stand in conflict with the right of 
free movement of EU residents [11].
Although migrating families might 
be confronted with the decision to either 
follow the schedule of the old or the new 
country of residence, there is little reason 
to believe that this will affect vaccine com-
pliance. And even if this problem does in 
fact exist, it would only affect a very small 
number of vaccinees: Taking the exam-
ple of Germany – the member state with 
the largest population (82 million) in the 
EU – national statistics from 2006 indi-
cate that 64,735 German residents moved 
to another MS; of them, 304 were children 
younger than 1 year of age and 869 were 
1–2 years old [12]. In other words, based 
on a birth cohort of around 700,000 new-
borns per year in Germany roughly be-
tween 0.04% and 0.12% per birth cohort, 
might have been affected by migration 
in 2006. The number of children actual-
ly confronted with substantially different 
schedules is certainly much smaller, be-
cause in many cases national immunisa-
tion schedules are identical or similar de-
pending on the exact age at which a child 
is moving. And even this small number 
of children will not necessarily encoun-
ter difficulties: Since vaccines are licensed 
commonly for the EU market by the Eu-
ropean Medicines Agency (EMEA) ev-
ery licensed vaccine product can be pur-
chased and used in every MS [13]. If a li-
censed vaccine is not easily available in 
one MS it can be imported from another 
MS. Thus, a started immunisation series 
in one MS can always be completed. From 
2001 to 2008, the Robert Koch Institute 
has received over 10,500 e-mail requests 
through its immunisation hotline for phy-
sicians and health care workers; only one 
of these requests dealt with the question 
how an immunisation series which had 
been started in another MS should be con-
tinued in Germany. In any case – with or 
without migration – it is the responsibil-
ity of the physician to decide which vac-
cine to administer, taking into account 
primarily national recommendations but 
also health status of the vaccinee and indi-
vidual and geographical risk assessment. 
Therefore, the issue of migration is negli-
gible in size and quality.
Lower vaccine prices
One argument favouring uniform im-
munisation schedules is that more coun-
tries could initiate joint negotiations with 
the manufacturers since the required 
products would be identical. Although 
this argument is initially appealing, it 
does not necessarily require uniform im-
munisations schedules: First of all several 
countries already have had identical im-
munisation schedules for many years, but 
to our knowledge none of them have yet 
come together to organise joint negotia-
tions for vaccine prices. Several EU MS 
do already negotiate successfully with 
vaccine manufacturers on a national ba-
sis. But in some EU MS the structure or 
organisation of health care systems does 
not allow the option of negotiations with 
vaccine manufactures. In Germany, for 
example, the vaccine market is not regu-
lated by public authorities and the govern-
ment does not have the possibility to ne-
gotiate with manufactures about the vac-
cine prices or products tailored to suit the 
German situation [14]. Only the German 
Statutory Health Insurances (SHI) are able 
to negotiate with the vaccine manufactur-
ers on a discount of vaccine prices [14]. 
Around 200 SHI exist in Germany and no 
agreement with respect to vaccine prices 
has been reached so far between a SHI and 
a manufacturer [15]. This is a good indi-
cation that uniform immunisation sched-
ules across the EU would not necessarily 
result in the ability of MS to jointly nego-
tiate lower vaccine prices.
Second, the principal basis for nego-
tiating lower prices for larger amounts of 
any given product is twofold. On the one 
hand a manufacturer can limit the varia-
tion of products and thus reduce produc-
tion cost; on the other hand a manufactur-
er can better estimate the market demand 
and thus optimize production according-
ly. For this however, it is not relevant when 
the buyer will actually use the product (i.e. 
at what age and how often a vaccine will 
be administered) but rather when and 
in what amount the product will be pur-
chased. Admittedly, certain immunisa-
tion schedules will eventually result in 
the need or possibility for vaccine com-
binations, which could indeed be seen as 
a common product specification. Never-
theless the largest potential of negotiating 
lower prices lies within the uniformity of 
product licensure. This potential which is 
already reached by the EMEA has yet to be 
used, and experiences to be gained with it, 
before going to the next step which would 
be to initiate the establishment of uniform 
immunisation schedules.
One might also argue that the main 
goal of the EU treaty is to create a com-
mon market, but its application to vac-
cines would simply mean that products 
are accessible and marketable through 
the EU [16]; this is already guaranteed by 
the uniform EMEA licensing procedure. 
But the EU treaty does not cover uniform 
recommendations indicating at what age 
a customer should use a certain product 
(i.e. vaccine).
Minimum effective schedules
In recent efforts of the ECDC to generate 
guidance on diphtheria-tetanus-pertussis 
(DTP) vaccination it has been argued that 
the guidance would only go as far as giv-
ing options for “minimal” effective doses 
[10]. This implies that it leaves all liberty 
to the national committees on immunisa-
tions (NCI) and to the individual prescrib-
ers to go beyond such minimal schedules. 
However, this is not necessarily the logi-
cal conclusion: In pharmacology in gener-
al the minimal effective dose is at the same 
time the only justified one. Because if ev-
idence suggests that more doses would 
not be more effective, any dose in addi-
tion to the effective minimum dose will 
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increase the risk for adverse effects. This 
is even particularly relevant in vaccinolo-
gy as it implies exposing healthy persons 
to a medical intervention, even if it is gen-
erally agreed that serious adverse effects 
of modern vaccines are very rare. There-
fore “minimal effective schedules”, a term 
that was selected to avoid the term “rec-
ommendations”, are in fact recommen-
dations and a NCI might face controver-
sial public arguments if it decides to issue 
a recommendation different from the EU 
minimal effective schedules, even if it is 
based on national peculiarities.
Fewer clinical trials
Different immunisation schedules will re-
sult in different interactions between dif-
ferent vaccines or vaccine components. 
This in fact results in the need for clini-
cal trials and will ultimately lead to more 
children or adults being exposed to such 
trials. While this is true, the same log-
ic would apply to the vaccine market di-
versity in general, which would ultimately 
lead to the conclusion that in Europe on-
ly one manufacturer should be in charge 
to develop and produce a specific vaccine. 
Certainly, the latter approach would re-
duce the overall need for clinical trials to 
a much larger extent than through estab-
lishment of uniform immunisation sched-
ules. However for other reasons it seems 
not to be worthwhile to strive for vaccine 
production monopoly in Europe.
Ease of data collection
Another argument stated by those favour-
ing uniform immunisation schedules is 
the idea that if they were more compa-
rable it would also be easier to generate 
comparable figures on vaccination cover-
age, vaccine effectiveness and vaccine safe-
ty. This would mean that all healthy indi-
viduals in Europe are supposed to submit 
themselves to one uniform medical inter-
vention just for the sake of making it eas-
ier for international public health institu-
tions and pharmaceutical companies to 
collect the data needed for such interven-
tions. Such argumentation would be large-
ly unethical. On the contrary, one might 
argue that the diversity of immunisation 
schedules actually allows large-size obser-
vational comparisons of effectiveness and 
safety of certain schedules. In addition, a 
uniform immunisation schedule within 
the EU will not necessarily be linked with 
uniform surveillance instruments in the 
different MS.
EU funded projects and projects now 
hosted at ECDC are already addressing 
those issues, such as the Vaccine Euro-
pean New Integrated Collaboration Ef-
fort (VENICE), which aims to encourage 
collection and dissemination of knowl-
edge and best practice relating to vacci-
nation [17]. One of the specific objectives 
of VENICE is to define common indi-
cators for monitoring the immunisation 
programmes across the MS. If the aim of 
an immunisation programme is defined 
consistently, then EU common monitor-
ing is possible while different immunisa-
tion schedules are used.
Another European-wide project is EU-
VAC.NET which was created for the pur-
poses of epidemiological surveillance and 
control of VPDs in the European commu-
nity [1]. In this network epidemiological 
data should be collected in order to sup-
port MS in the decision making process of 
new vaccines and in evaluation of existing 
immunisation strategies.
Increased vaccination coverage
In the documents discussing the minimal 
effective schedule it is stated that these 
schedules will increase the vaccination 
coverage [2, 10]. There seems to be no re-
al evidence for this statement. As already 
mentioned issues regarding vaccine de-
livery and timing of vaccinations seem to 
influence the vaccination coverage. Again 
we would like to refer to an example from 
Germany where the measles-mumps-ru-
bella (MMR) vaccination is given in two 
doses within the second year of life. This 
schedule is divergent to MMR vaccina-
tion schedules in many other MS, where 
the second dose MMR is given for exam-
ple by school entry [1]. Although there are 
no uniform MMR vaccination schedules 
within Europe, vaccination coverage of 
the second dose MMR vaccine increased 
considerable in Germany from 33% cover-
age in the 5 to 6-year-old children in 2002 
to 88% coverage in 2007, because in 2001 
the schedule changed and the second dose 
MMR should be administered before the 
2nd birthday [18, 19]. Other local aspects 
are influencing the vaccination uptake as 
attitudes of the population towards im-
munisation in general and its awareness 
in respect to the safety of a certain vac-
cine or the promoting of immunisation by 
the physicians, midwives or other medical 
care givers and by the media, respective-
ly. Finally, the aspect of reimbursement of 
vaccinations – which is organised differ-
ently in the MS – might influence vacci-
nation coverage, as well.
Under careful consideration of the ar-
guments for the proposal to facilitate one 
uniform childhood immunisation sched-
ule or uniform schedules in the EU, we 
feel that they are either quantitatively and 
qualitatively not relevant or substantial 
(mobility of residents, minimal effective 
schedule, ease of data collection, increas-
ing vaccination coverage) or if they are 
relevant (lower vaccine prices, fewer clin-
ical trials) various other measures could 
more effectively address them.
Conclusion
EU-wide establishment of uniform child-
hood immunisation schedules could 
have some benefits, but it is not a goal by 
itself and should rather be seen as logical 
and desirable by-product of two devel-
opments: firstly, increased agreement on 
common vaccination goals and general 
values and secondly, improved evidence 
based decision making approaches for 
recommendations on immunisation.
The EU and its respective agencies such 
as the EMEA and the ECDC should focus 
on facilitating those two developments. 
This could be accomplished by increas-
ing support for vaccine-related epidemi-
ological research, by continuing the de-
velopment of a commonly agreed sys-
tem for generating and grading the sci-
entific evidence, by conducting or coor-
dinating epidemiological research in or-
der to generate the missing evidence, by 
improving comparability of surveillance 
data and by moderating the agreement 
on immunisation goals between the MS. 
We appreciate that these activities are al-
ready taking place and we hope they will 
be strengthened and also increasing-
ly involve NCIs and other relevant bodies 
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in the EU MS. The cooperation between 
the Advisory Committee on Immunisa-
tion Practices (ACIP) in the United States 
and its “liaison organisations” could be a 
good example for this [4].
If the EU and its MS have very effective 
tools at hand to improve and lay out the 
evidence, it would then be up to the NCIs 
to generate recommendations based 
on this evidence. National immunisa-
tion schedules will still differ to some ex-
tent because of different values in differ-
ent societies and because of the various 
other reasons discussed above, but those 
differences will then be well justified. 
“Harmonisation” of immunisation sched-
ules resulting from such a process may 
take somewhat longer than political-
ly motivated council recommendations 
or selected options of minimal effec-
tive schedules. However we believe the 
evidence-based, multifaceted approach 
proposed above is likely to be more sus-
tainable and thus more effective in pre-
venting disease in the EU.
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